FAQ on Aditxt Inc.'s May 2 Update Featuring Mayo Clinic's Dr. Charles Howe on ADI-100™ Preclinical Study

What is the main topic of the May 2 update hosted by Aditxt Inc.?

The main topic is the discussion of key findings from a preclinical study of ADI-100, the lead therapeutic candidate from Aditxt’s subsidiary, Adimune Inc., with a focus on advancements in immune modulation therapy.

Who will be featured in the Aditxt Inc. update on May 2, 2025?

Dr. Charles Howe of the Mayo Clinic, Dr. Shahrokh Shabahang, Aditxt’s Chief Innovation Officer, and Dr. Friedrich Kapp, Co-CEO of Adimune, will be featured in the update.

Why is the preclinical study of ADI-100 significant?

The study is significant as it represents the latest advancements in immune modulation therapy, potentially addressing urgent health challenges through innovative health solutions.

How can I view the full press release about the May 2 update?

The full press release can be viewed at https://ibn.fm/3imFv.

What is Aditxt Inc.’s mission?

Aditxt’s mission is to ‘Make Promising Innovations Possible Together’ by accelerating health innovations through its ecosystem of research institutions, industry partners, and shareholders.

What programs does Aditxt Inc. currently operate?

Aditxt currently operates programs focused on immune health and precision health, with plans to introduce additional programs dedicated to public health and women’s health.

Where can I find the latest news and updates relating to ADTX?

The latest news and updates relating to ADTX are available in the company’s newsroom at https://ibn.fm/ADTX.

What is the significance of Aditxt’s arrangement with Appili Therapeutics Inc. and Evofem?

These arrangements aim to expand Aditxt’s programs into infectious diseases and women’s health, subject to certain conditions, to collectively advance its mission of discovering and deploying innovative health solutions.